Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.
Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company’s ...
It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...
Tech billionaire investor Bill Gates was given approval to "secretly" spray synthetic RNA on food products in the United States through a company called Terrana Biosciences. One Facebook post ...
-- Novel approach to gene knockdown uses proprietary CASi (Conditionally Activated siRNA) molecules optimized to “switch” on, activating siRNA therapeutics only in selected cells -- -- CASi platform, ...
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, ...
Cardiovascular disease (CVD) is the leading cause of death globally, and combating this range of complex disorders presents numerous challenges. Scientists seek innovative approaches to address this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results